TY - JOUR
T1 - Spectrum of Restrictive and Infiltrative Cardiomyopathies
T2 - Part 1 of a 2-Part Series
AU - Pereira, Naveen L.
AU - Grogan, Martha
AU - Dec, G. William
N1 - Publisher Copyright:
© 2018 American College of Cardiology Foundation
PY - 2018/3/13
Y1 - 2018/3/13
N2 - Restrictive cardiomyopathies are the least common form of heart muscle disease. They are characterized as infiltrative and noninfiltrative, storage diseases, and endomyocardial disorders. Genetic diseases commonly present during childhood or adolescence. However, a growing percentage of elderly patients with heart failure with preserved ejection fraction are being recognized as having forms of restrictive cardiomyopathy, particularly cardiac amyloidosis. Noninvasive evaluation has replaced endomyocardial biopsy in the diagnostic evaluation of most suspected etiologies. The detection of infiltrative cardiomyopathies, including lysosomal and glycogen storage disorders, iron overload, and amyloidosis (both light chain amyloidosis and transthyretin amyloidosis variants), as well as inflammatory diseases such as sarcoidosis has slowly led to improved outcomes via disease-specific therapies.
AB - Restrictive cardiomyopathies are the least common form of heart muscle disease. They are characterized as infiltrative and noninfiltrative, storage diseases, and endomyocardial disorders. Genetic diseases commonly present during childhood or adolescence. However, a growing percentage of elderly patients with heart failure with preserved ejection fraction are being recognized as having forms of restrictive cardiomyopathy, particularly cardiac amyloidosis. Noninvasive evaluation has replaced endomyocardial biopsy in the diagnostic evaluation of most suspected etiologies. The detection of infiltrative cardiomyopathies, including lysosomal and glycogen storage disorders, iron overload, and amyloidosis (both light chain amyloidosis and transthyretin amyloidosis variants), as well as inflammatory diseases such as sarcoidosis has slowly led to improved outcomes via disease-specific therapies.
KW - amyloidosis
KW - heart failure
KW - restrictive cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=85042329365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042329365&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.01.016
DO - 10.1016/j.jacc.2018.01.016
M3 - Review article
C2 - 29519355
AN - SCOPUS:85042329365
SN - 0735-1097
VL - 71
SP - 1130
EP - 1148
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 10
ER -